The ASCEND-ND trial: study design and participant characteristics

ABSTRACT Background Anaemia is common in chronic kidney disease (CKD) and assessment of the risks and benefits of new therapies is important. Methods The Anaemia Study in CKD: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) trial includes adult patients with CKD Stages 3–5, not using erythropoiesis-stimulating agents (ESAs) with screening haemoglobin (Hb) 8–10 g/dL or receiving ESAs with screening Hb of 8–12 g/dL. Participants were randomized to daprodustat or darbepoetin alfa (1:1) in an open-label trial (steering committee- and sponsor-blinded), with blinded endpoint assessment. The co-primary endpoints are mean change in Hb between baseline and evaluation period (average over Weeks 28–52) and time to first adjudicated major adverse cardiovascular (CV) event. Baseline characteristics were compared with those of participants in similar anaemia trials. Results Overall, 3872 patients were randomized from 39 countries (median age 67 years, 56% female, 56% White, 27% Asian and 10% Black). The median baseline Hb was 9.9 g/dL, blood pressure was 135/74 mmHg and estimated glomerular filtration rate was 18 mL/min/1.73 m2. Among randomized patients, 53% were ESA non-users, 57% had diabetes and 37% had a history of CV disease. At baseline, 61% of participants were using renin–angiotensin system blockers, 55% were taking statins and 49% were taking oral iron. Baseline demographics were similar to those in other large non-dialysis anaemia trials. Conclusion ASCEND-ND will define the efficacy and safety of daprodustat compared with darbepoetin alfa in the treatment of patients with anaemia associated with CKD not on dialysis.

[1]  J. Barratt,et al.  Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES) , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  Kimberly A. Walters,et al.  Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. , 2021, The New England journal of medicine.

[3]  S. Solomon,et al.  Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  S. Fishbane,et al.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. , 2021, Journal of the American Society of Nephrology : JASN.

[5]  W. Winkelmayer,et al.  Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  Kimberly A. Walters,et al.  Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD:  Design and Baseline Characteristics. , 2020, American heart journal.

[7]  M. Nangaku,et al.  Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[8]  C. Jacquelinet,et al.  Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD. , 2020, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[9]  M. Nangaku,et al.  A 24‐Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients , 2020, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[10]  J. Lepore,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis , 2018, Clinical kidney journal.

[11]  Sung Gyun Kim,et al.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease , 2018, Clinical kidney journal.

[12]  J. Górriz,et al.  Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease , 2018 .

[13]  V. Perkovic,et al.  Cardiovascular disease in patients with chronic kidney disease , 2014, Nephrology.

[14]  J. Adamson,et al.  Notice , 2012, Kidney International Supplements.

[15]  H. Uno,et al.  Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.

[16]  R. Garrick A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[17]  H. Uno,et al.  Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  R. Califf,et al.  Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. , 2008, Kidney international.

[19]  C. Stehman-Breen,et al.  Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[20]  Ashutosh Kumar Singh,et al.  Editorial: The Optimal Hemoglobin in Dialysis Patients— A Critical Review , 2007, Seminars in dialysis.

[21]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[22]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[23]  H. Feldman,et al.  Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[25]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.

[26]  S. Holm A Simple Sequentially Rejective Multiple Test Procedure , 1979 .